18th May 2015 06:50
LONDON (Alliance News) - Oxford Pharmascience Group PLC Monday said it has started dosing in its pilot clinical study of 250mg OXPzero Naproxen (OXP005), the drug it is developing as an alternative to standard naproxen tablets with a reduced gastrointestinal side effect profile.
The company, which is redeveloping medicines in an attempt to make them safer and easier to take, recently announced a successful proof-of-concept pharmacokinetic study for the drug, and has now progressed to an endoscopic evaluation study to prove reduced gastrointestinal irritation.
The purpose of the Phase I, randomised, controlled pilot study is to assess the severity of upper gastrointestinal damage via endoscopic assessment following seven days treatment of 1 g a day naproxen dosed as either OXP005 or Naprosyn. It expects headline results to be released late in the second quarter or early in the third quarter of 2015.
"Successful study data will confirm the results observed last year with OXPzero Ibuprofen demonstrating the class effect of the technology and putting the company in a strong position going into partnering discussions later this year," Chief Executive Marcelo Bravo said.
By Steve McGrath; [email protected]; @stevemcgrath1
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Pharmascience Group